MMSI

Business Context and Reporting Period

Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2005
Business Overview: Merit Medical designs, manufactures, and markets medical devices, primarily for interventional cardiology and radiology. The company reported record revenues for the quarter, driven by new product introductions and the integration of a newly acquired procedure tray business.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7% ($2.6 million) year-over-year. Growth was driven by a 2% increase from new products, 1% from the new procedure tray business (acquired late 2004), and 1% from favorable foreign exchange rates.
• Margin Compression: Gross margin decreased slightly to 43.4% from 43.6%. Management attributes a 1.1% negative impact to the newly acquired procedure tray business in Richmond, Virginia. Excluding this business, margins would have been 44.5%.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses rose to 24.1% of sales (from 22.7%). Increases were due to a $200,000 distribution agreement buy-out, $155,000 in severance, and $72,000 in external audit fees for Sarbanes-Oxley compliance. R&D expenses increased to 3.8% of sales to support seven new product launches.
• Net Income Decline: Net income decreased 6.9% to $4.1 million. This was primarily due to higher operating expenses and a one-time $100,000 litigation settlement gain recorded in Q1 2004 that did not recur.
• Cash Flow: Net cash provided by operating activities decreased to $5.1 million from $6.5 million. Investing activities consumed $9.9 million, primarily due to $9.7 million in capital expenditures for new facilities in South Jordan, Utah.

Guidance, Outlook, and Risks

• Capital Expenditures: The company is investing heavily in capacity expansion. Approximately $3.7 million was paid in Q1 for facility construction in Utah, with $10.1 million remaining to complete the project. An additional $2.5 million is anticipated for production equipment.
• Acquisitions: On March 11, 2005, Merit acquired assets of Sub-Q, Inc. for approximately $1.07 million (including a $1.0 million note applied to the price) to develop vascular sealing devices and gel foam products. In April 2005, the company purchased a 102,000 sq. ft. building in Chester, Virginia for $3.8 million to support procedure tray production.
• Accounting Changes: Merit currently uses the intrinsic value method (APB 25) for stock-based compensation. Adoption of SFAS 123R (fair value method) is planned for January 1, 2006. Pro forma net income for Q1 2005 would have been $1.7 million (vs. reported $4.1 million) under the new standard, largely due to the acceleration of vesting on 427,448 options.
• Market Risks: The company faces exposure to Euro and British Pound Sterling fluctuations, which accounted for 13.1% of revenues. A net exposure of approximately $1.2 million (receivables less payables) was hedged via forward contracts. Other risks include product recalls, regulatory approval delays, and competition.

Investor Verification Checklist

• Stock-Based Compensation Impact: Verify the magnitude of the pro forma earnings reduction ($2.4 million expense) upon the adoption of SFAS 123R in 2006.
• Capital Expenditure Burn Rate: Monitor the $10.1 million remaining for the Utah facility and the $2.5 million for equipment to ensure cash flow adequacy.
• Procedure Tray Integration: Assess whether the negative margin impact from the new procedure tray business improves as the operation scales.
• Debt and Liquidity: Confirm the status of the $500,000 revolving credit facility and the potential to restore it to $35 million if needed.
• Foreign Exchange Sensitivity: Review the effectiveness of hedging strategies given the 13.1% revenue exposure to non-USD currencies.